Vantage logo

CD47 is worth $4.9bn to Gilead

A $4.9bn buyout of Forty Seven means that Gilead remains focused on oncology, though cell therapy bulls are none the wiser.

Vantage logo

Lilly spends big on mirikizumab

With eight phase III trials in three different indications, Lilly is investing heavily in mirikizumab. The first pivotal data, in psoriasis, will emerge soon.

Vantage logo

Forty Seven bucks the trend

Tackling the CD47 pathway has seen off several industry players, but Forty Seven continues proudly flying the flag.